DAJY(SZ:002030)2024-09-13 17:34Group 1: Market Demand and Performance - The company's molecular diagnostic product shipment volume has significantly increased compared to 2019, despite a notable decline in product prices [2] - The overall sales volume of the company's products is on an upward trend, with tumor detection products like EB and HPV showing certain sales figures [2] - The market demand for molecular diagnostic reagents is increasing due to rising health awareness and expanding medical insurance coverage [2] Group 2: Company Operations and Changes - The company has changed its accounting firm this year due to the expiration of the continuous appointment period as per regulatory guidelines [2] - The total number of employees has decreased compared to 2023 due to market changes and structural adjustments [2] - R&D expenditure for the first half of the year was 187 million, and it is expected to decrease compared to 2023 due to adjustments in R&D direction and focus [2][3] Group 3: Future Strategies - The company aims to actively promote technological and product innovations to find new revenue growth points [2] - Efforts are being made to reduce unnecessary expenses and seek more efficient solutions in the R&D field [3]